Global Head Lice Drug Market by Type (Cream and Lotion, Shampoo, Lice Removal Kits, and Others), By Application (Adults and Children), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Forecast (2022-2028)

The global head lice drug market is anticipated to grow at a significant CAGR during the forecast period (2022- 2028). Head lice are small, wingless, blood-sucking insects that infest in hair. They feed off the blood from scalp which causes irritation or sometimes leads to big pimples on the head. Adult Head lice feed the blood from the human scalps and it can survive 30 days on human scalps. These are mostly found in women and children. Head lice are transferred from one person to another due to direct contact. Head lice are caused by symptoms such as intense itching, tingling feeling on the movement of hair, and sores on the scalp, neck, and shoulders. Head lice are caused by poor personal hygiene. The growing burden of head lice in both rural and urban areas owing to increasing pollution and direct contact with large groups of people at schools, day care clinics, salons, etc. are some of the factors that are driving the market growth. For instance, Lice Clinics of America offers safety and urgent treatment of head lice and promotes the use of lice removal kits through digital campaigns to curb the increasing prevalence of head lice in the US.

In the region, North America is anticipated to dominate the global head lice drug market during the forecast period. This is mainly due to the presence of a larger infestation pool and an increasing children population. In the North American region, the US holds the largest market share owing to the FDA approvals for head lice drugs. For instance, in August 2020, Uniseed investee company Hatchtech, developing an innovative prescription head lice product, declared that its commercialisation partner, Dr Reddy’s Laboratories, has achieved US FDA approval of Xeglyze (abametapir) Lotion 0.74% for the topical treatment of head lice infestation in patients 6 months of age and older.  Xeglyze was developed by Hatchtech who completed a full development program through to the submission of a new drug application by the company in September 2015.  At the same time, Hatchtech sold the rights to Xeglyze to Dr Reddy’s Laboratories for selected territories, including the US.

Some major companies in the market include Bayer AG, and Perrigo Co. plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in 2019, PIC Corp. entered an agreement with ICB Pharma, a European pharmaceutical company for exclusive licensing and distribution of Nitolic Head Lice and Nits Treatment Kit.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Bayer AG, and Perrigo Co. plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Head Lice Drug Market Report by Segment

By Type

• Creams and Lotion
• Shampoo
• Lice Removal Kits
• Others

By Application

• Adults
• Children

By Distribution Channel

• Hospitals Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Head Lice Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa